If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1

$50.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Mucosal immune responses are an early and important line of defense against pathogens. The current understanding of the mucosal immune system allows us to consider the use of nasal immunization for induction of antigen-specific immune responses at the mucosal surface and the systemic compartment. Mucosal adjuvants are key for developing novel mucosal vaccines and represent 1 approach to improving mucosal and systemic immunity. However, few mucosal vaccine adjuvants are currently approved for human use. Neisseria meningitidis B proteoliposome-derived cochleate (AFCo1 - Adjuvant Finlay Cochleate 1) has been demonstrated to be a potent mucosal adjuvant. The present work demonstrates that intranasal immunization of 3 doses of tetanus toxoid (TT) coadministered with AFCo1 in mice promotes high systemic and mucosal responses. The anti-TT IgG serum titers and the mucosal anti-TT IgA in saliva and vaginal wash were significantly higher than TT alone. The analysis of antibody subclasses showed that intranasal administration of AFCo1 + TT induced not only IgG1 but also IgG2a anti-TT antibodies at levels comparable to those obtained with TT vaccine (vax-TET). These data support the fact that AFCo1 is a potent mucosal adjuvant in nasal immunization to a coadministered protein antigen.

Les réponses immunes muqueuses constituent une ligne de défense précoce et importante contre les pathogènes. Notre connaissance actuelle du système immunitaire des muqueuses nous permet de considérer l’utilisation d’une immunisation nasale pour induire des réponses immunes antigéniques spécifiques muqueuses et systémiques. Les adjuvants muqueux sont la clé du développement de nouveaux vaccins muqueux et constituent une approche permettant d’améliorer l’immunité muqueuse et systémique. Cependant, il n’y a que peu d’adjuvants vaccinaux muqueux présentement approuvés pour une utilisation chez l’humain. Un cochléate de protéoliposomes de Neisseria meningitidis B (AFCo1 - Adjuvant Finlay cochleate 1) s’est avéré puissant comme adjuvant muqueux. Le travail présent démontre que l’immunisation intranasale avec 3 doses d’anatoxine tétanique (TT) administrées conjointement à l’adjuvant AFCo1 chez la souris favorise des réponses systémiques et muqueuses élevées. Les titres d’IgG anti-TT sériques et d’IgA anti-TT muqueux dans la salive et le lavage vaginal étaient plus élevés qu’avec la TT seule. L’analyse des sous-classes d’anticorps a montré que l’administration intranasale d’AFCo1 + TT induisait non seulement des anticorps IgG1, mais aussi des anti-TT IgG2a à des niveaux comparables à ceux du vaccin TT (vax-TET). Ces données appuient le fait que l’AFCo1 est un adjuvant muqueux puissant lors d’une immunisation nasale conjointe à l’administration d’un antigène peptidique.

Document Type: Research Article

Publication date: March 1, 2011

More about this publication?
  • Published since 1954, this monthly journal contains new research in the field of microbiology including applied microbiology and biotechnology; microbial structure and function; fungi and other eucaryotic protists; infection and immunity; microbial ecology; physiology, metabolism and enzymology; and virology, genetics, and molecular biology. It also publishes review articles and notes on an occasional basis, contributed by recognized scientists worldwide.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Sample Issue
  • Reprints & Permissions
  • ingentaconnect is not responsible for the content or availability of external websites

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more